INTRODUCTION {#Sec1}
============

Stargardt disease (STGD1, MIM 248200) is one of the most frequent inherited retinal diseases (IRDs), with an estimated prevalence of 1/8000--1/10,000. The underlying disease gene for STGD1 is the large ATP-binding cassette subfamily A member 4 gene (*ABCA4*, MIM 601691), consisting of 50 coding exons.^[@CR1]^ Apart from STGD1, a juvenile macular dystrophy, biallelic *ABCA4* variants have been linked to a spectrum of autosomal recessive IRD phenotypes, varying from cone-rod dystrophy (CRD), atypical retinitis pigmentosa (RP), fundus flavimaculatus, generalized choriocapillaris dystrophy (GCCD), to rapid-onset chorioretinopathy (ROC), jointly named *ABCA4*-associated disease.^[@CR2]--[@CR5]^ A genotype--phenotype correlation model was proposed to explain this large variety of phenotypes attributed to biallelic pathogenic variants in *ABCA4*, linking the amount of residual activity of ABCA4 to the corresponding phenotype. According to this model, patients with two severe variants (null alleles) present with atypical RP or ROC while a severe variant in *trans* to a moderate variant gives rise to CRD, and a severe and mild variant or two moderate variants give rise to STGD1 (refs. ^[@CR6],[@CR7]^). The variant spectrum of *ABCA4*-associated disease is characterized by vast allelic heterogeneity, with over 800 variants identified (<https://databases.lovd.nl/shared/genes/ABCA4>), the majority of which are located in the coding region of *ABCA4*. Furthermore, a large number of intronic noncanonical splice site variants have been identified, with c.5461--10T\>C being the third most frequent pathogenic variant.^[@CR8],[@CR9]^ Previous studies indicate that copy-number variations (CNVs) represent only a minor fraction of the variant spectrum.^[@CR3],[@CR7],[@CR10]--[@CR18]^ This large number of (likely) pathogenic variants in *ABCA4* can only explain 60--75% of STGD1 and other monoallelic *ABCA4*-associated disease cases, suggesting missing heritability in noncoding regions. Indeed, we and others uncovered noncoding deep-intronic variants as second pathogenic alleles.^[@CR10],[@CR19]--[@CR22]^ Braun et al.^[@CR19]^ and Zernant et al.^[@CR20]^ identified a subset of noncoding variants with a presumed effect on splicing. We found the deep-intronic variant c.4539+2001G\>A (denoted as V4) as the second missing allele in more than 25% of Belgian monoallelic STGD1 patients, representing the first noncoding founder pathogenic variant in *ABCA4* (ref.^[@CR21]^). Schulz et al.^[@CR22]^ analyzed the coding region of *ABCA4* and parts of intron 30 and 36, known to harbor deep-intronic variants, in a large (*p* = 335) German STGD1 cohort. They identified rare deep-intronic variants in only four patients and reported six putative risk-modulating common variants, one of which is the hypomorphic recurrent *ABCA4* variant c.5603A\>T p.(Asn1868Ile) (minor allele frequency \[MAF\] 7%, Genome of the Netherlands database \[GoNL\]). Zernant et al.^[@CR23]^ demonstrated that this variant contributes to 10% of the *ABCA4* disease alleles, representing the second missing allele in over 50% of monoallelic STGD1 cases, often displaying a late-onset phenotype with foveal sparing.

Noncoding deep-intronic splice variants represent potential therapeutic targets for approaches such as antisense oligonucleotide (AON)-mediated rescue or CRISPR/Cas9-mediated correction of deep-intronic pathogenic variants, as illustrated for *CEP290*, *USH2A*, *OPA1*, and recently for *ABCA4*, emphasizing the relevance of this study.^[@CR24]--[@CR27]^

Taken together, this prompted us to elucidate the missing heritability in a cohort of 67 Belgian and German patients diagnosed with *ABCA4*-associated disease, with only one heterozygous (*p* = 64) or no (*p* = 3) identified *ABCA4* pathogenic variant after first-line screening.

MATERIALS AND METHODS {#Sec2}
=====================

Patient cohort {#Sec3}
--------------

Patients consented to this study, which adhered to the tenets of the Declaration of Helsinki (protocols B670201525349 and B670201734438). All individuals had a clinical diagnosis of an *ABCA4*-associated disease, such as STGD1 (Table [S1](#MOESM1){ref-type="media"}), and underwent testing of the coding region of *ABCA4*, revealing either one pathogenic variant (*p* = 64) or no pathogenic variant (*p* = 3) (Figure [S1](#MOESM3){ref-type="media"}). Info on clinical assessments and genotype--phenotype correlations can be found in Supplemental [Methods](#MOESM2){ref-type="media"}.

Locus enrichment {#Sec4}
----------------

Using a custom HaloPlex Target Enrichment kit (Agilent, Santa Clara, CA, USA), a conserved block of synteny encompassing the *ABCA4* gene (chr1:94337885-94703604, GrCh37/hg19 assembly) was enriched.^[@CR28]^ Approximately 98% of the region could be covered, while gaps often corresponded with repeat-rich areas (Figure [S2](#MOESM3){ref-type="media"}). The locus and the entire *ABCA4* gene were sequenced with an average coverage depth of 263.6× and 343.4×, respectively.

Next-generation sequencing and data analysis {#Sec5}
--------------------------------------------

Samples underwent targeted next-generation sequencing (NGS) (MiSeq, Illumina, CA, USA). Read mapping, single-nucleotide variant, structural variant, and indel calling and subsequent variant identification and annotation were performed using CLC Bio Software (CLC Bio Genomics Workbench; QIAGEN, Germany).  Annotations included frequencies from a subset of the UK National Institute for Health Research (NIHR) BioResource Rare Diseases Whole Genome Sequencing data set containing 7322 individuals without a known IRD, the Genome Aggregation Database (gnomAD) and GoNL databases, presence within published minor exons of *ABCA4* or 200 bp of neighbouring sequence (Table S2), overlap with long noncoding RNAs (lncRNAs) (Table S2) and published noncoding *ABCA4* variants (Table S3), and presence in candidate regulatory regions, as determined by ATAC-seq, RNA-seq, H3K27Ac, and H3K4me2 ChIP-seq data generated on adult human retina (Table [S4; unpublished data:](#MOESM1){ref-type="media"} Cherry et al.,doi.org/10.1101/412361).^[@CR19]--[@CR22],[@CR29]^ Further annotation was performed via Alamut Batch (Interactive Biosoftware, France). A custom Lua script was used for additional data processing.

*ABCA4* variant analysis {#Sec6}
------------------------

First, variants within *ABCA4* (NM_00350.2) were investigated. After identifying known pathogenic variants, only variants with MAF ≤1% in the aforementioned population databases were selected. Per individual, all remaining rare noncoding variants within *ABCA4* were analyzed for predicted effects on splice sites, exonic splice enhancers (ESEs), and splice silencers using splice annotations of Alamut Batch, Alamut Visual (Interactive Biosoftware, France), and Human Splicing Finder (<http://www.umd.be/HSF3/>). Second, variants located within putative regulatory regions in the enriched locus were selected and annotated (unpublished data, Cherry et al., 10.1101/412361, RegulomeDB). In the absence of candidate variants, rare *ABCA4* variants outside of the regulatory regions were also investigated. Polymerase chain reaction (PCR) primers for validation are listed in Table [S5](#MOESM1){ref-type="media"}. If possible, segregation results were used for filtering.

In vitro splicing assays {#Sec7}
------------------------

### Minigenes {#Sec8}

Genomic DNA from patients who are heterozygous carriers of putative splice variants was used for creating wild-type (WT) and mutant minigenes for seven variants (Table [S6](#MOESM1){ref-type="media"}); minigene assays were performed as described.^[@CR30]^ Primers and conditions are listed in Table [S7](#MOESM1){ref-type="media"}.

### Midigenes {#Sec9}

We used the midigene library and protocol previously described to create WT and mutant midigenes for six variants and to perform midigene assays (Tables [S6](#MOESM1){ref-type="media"} and [S8](#MOESM1){ref-type="media"}) (ref. ^[@CR30]^). Transfection was performed in triplicate in HEK 293-T cells.

AON-mediated rescue experiments {#Sec10}
-------------------------------

### AON design {#Sec11}

Per variant, AONs with a phosphorothioate backbone with a 2-*O*-methyl sugar modification (2OME/PS) were designed, as described (Table [S9](#MOESM1){ref-type="media"}) (ref. ^[@CR31]^). In addition, a sense oligonucleotide (SON) was synthesized. Synthesis was done by Eurogentec (Belgium). An AON concentration of 0.5 µM was used.

### In vitro rescue studies in transfected HEK 293-T cells {#Sec12}

HEK 293-T cells were transfected with 1.5 µg of WT or mutant midigene construct. After 24 hours, each well was trypsinized and subdivided in 5 wells of a 24-well plate. After reattachment, cells were transfected with the AON, the SON, or not treated (NT) (FuGENE HD Transfection Reagent, Promega, The Netherlands). After 48 hours, RNA was isolated (NucleoSpin RNA kit, Macherey-Nagel, Germany) followed by complementary DNA (cDNA) synthesis (iSCRIPT cDNA synthesis kit, Bio-Rad, Belgium). A PCR with 50 ng of cDNA was performed of which 10 µl was loaded on a 2% agarose gel (primers: Table [S10](#MOESM1){ref-type="media"}). Rhodopsin was used as transfection and loading control. Two independent experiments were performed. Quantification of transcript ratios was done via a Fragment Analyzer Auto Capillary Electrophoresis System (Advanced Analytical Technologies, Inc., France).

### In vitro rescue studies in patient-derived fibroblast cells {#Sec13}

Patient's fibroblasts (c.4539+1106C\>T) were seeded and transfected with either 0.5 µM of AON, SON, or empty liposomes (NT). Cycloheximide (CHX) was added as a nonsense-mediated decay (NMD) blocker. Four hours later RNA was isolated followed by cDNA synthesis (Invitrogen SuperScript IV VILO Master Mix, Thermo Fisher Scientific, Belgium). For each PCR, 80 ng of cDNA was used, except for actin (50 ng) (primers: Table [S10](#MOESM1){ref-type="media"}). Then, 20 µl of each *ABCA4* reaction was loaded onto a 2% agarose gel using 10 µl of the actin reaction as loading control. Experiments were performed in two independent replicates. Quantification of the transcripts was performed using the capillary electrophoresis system described above.

In vitro dual-luciferase assays {#Sec14}
-------------------------------

### Constructs and assays {#Sec15}

Inserts were PCR amplified using genomic reference DNA (Roche) and primers containing restriction sites (Table [S11](#MOESM1){ref-type="media"}). After restriction, the insert was cloned into a pgl4.23 or pgl4.10 vector (Promega, The Netherlands) and mutagenized (Q5-Site-Directed Mutagenesis Kit, New England Biolabs, France). hTert RPE-1 cells (ATCC, VA, USA) were transfected with 1.5 µg WT or mutant luciferase construct and a *Renilla* reporter vector (pRL, Promega, The Netherlands) (Lipofectamine 3000, Thermo Fisher Scientific, Belgium). Experiments were performed in triplicate, and a minimum of six independent experiments were performed for five variants (Table [S12](#MOESM1){ref-type="media"} and Figure [S3](#MOESM3){ref-type="media"}). Assays were performed using the Dual-Luciferase Reporter Assay system and Glomax 96 microplate luminometer (Promega, The Netherlands).

### Statistical data analysis {#Sec16}

A hierarchical generalized linear mixed model (HGLMM) was fitted to the normalized relative luminometer unit values (normalized luciferase/*Renilla* RLU ratios). Additional information can be found in Supplemental [Methods](#MOESM2){ref-type="media"}.

CNV analysis {#Sec17}
------------

Locus resequencing NGS data of all patients was mapped with Burrows--Wheeler Aligner (BWA) against the hg19 human reference genome, followed by local realignment of reads with Genome Analysis Toolkit (GATK) and CNV detection using the R package ExomeDepth.^[@CR32]--[@CR34]^ CNVs were annotated with ANNOVAR.^[@CR35]^ Furthermore, an in-house developed customized array comparative genomic hybridization (CGH) platform (arrEYE) was used for high-resolution CNV analysis of coding and noncoding regions of *ABCA4* and other retinal disease genes in a subset of ten patients (Figure [S4](#MOESM3){ref-type="media"}) (ref. ^[@CR36]^). Data was analyzed using the ViVar platform (<https://vivar.cmgg.be>). CNVs were confirmed and delineated using (junction) PCRs (Supplemental [Methods](#MOESM2){ref-type="media"}).

Assessment of the underlying mechanisms of the identified CNVs {#Sec18}
--------------------------------------------------------------

For each CNV an extensive bioinformatics analysis was performed as previously described^[@CR37]^ (Supplemental [Methods](#MOESM2){ref-type="media"}). Microhomology at the breakpoints was assessed using ClustalW (Figure [S5](#MOESM3){ref-type="media"}). If both breakpoints of a CNV overlap with a repetitive element, the consensus sequence was retrieved from the Dfam database and sequence identity between the repetitive elements was determined using BLAST2. The potential for formation of non-B DNA conformations in the breakpoint regions was examined using the non-B DNA motif search tool (nBMST); and QGRS Mapper. Fuzznucc was used to investigate the presence of 40 sequence motifs (Tables [S13](#MOESM1){ref-type="media"} and [S14](#MOESM1){ref-type="media"}).

RESULTS {#Sec19}
=======

Enrichment and targeted resequencing of the *ABCA4* locus {#Sec20}
---------------------------------------------------------

Targeted resequencing revealed 5840 variants with MAF ≤1% in 67 patients (87 variants/patient) located within the sequenced region (365 kb) of which 439 variants are located within *ABCA4* (6.5 variants/patient). Elimination of known pathogenic variants and certain variants in *cis* with these variants further reduced the number of candidate pathogenic variants to 121 variants, occurring 169 times (2.5 variants/patient) (Table [S15](#MOESM1){ref-type="media"}). Thirteen candidate splice variants were selected for analysis via splice assays (Table [S6](#MOESM1){ref-type="media"}).

Identification and functional assessment of novel noncoding (deep-)intronic splice variants {#Sec21}
-------------------------------------------------------------------------------------------

### Summary {#Sec22}

Overall, a splice effect was demonstrated by in vitro splice assays for nine intronic variants (*n* = 24) found in 21 monoallelic patients and 2 patients without prior identified pathogenic variants: c.161--23T \>G (*n* = 1), c.769--784C \>T (*n* = 1), c.859--540C\>G (*n* = 1), c.3191--11T\>A (*n* = 1), c.4253+43G\>A (*n* = 8), c.4539+1106C\>T (*n* = 2), c.4539+2001G\>A (*n* = 7), c.4539+2064C\>T (*n* = 2), and c.5197--557G\>T (*n* = 1) (Fig. [1](#Fig1){ref-type="fig"}, Fig. [2](#Fig2){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}, and Table [S1](#MOESM1){ref-type="media"}). Splice predictions are listed in Table [S16](#MOESM1){ref-type="media"}. Splice assays for c.769--784C\>T, c.4253+43G\>A, and c.4539+2001G\>A, also found in a Dutch cohort using the same resequencing approach, are reported by Sangermano et al. (this issue) and Albert et al. (ref. ^[@CR26],[@CR38]^).Fig. 1**Minigene and midigene results for intronic** ***ABCA4*** **splice variants.** For each depicted variant (**a-f**) an agarose gel image is shown on the left, representing the reverse transcription polymerase chain reaction (RT-PCR) product derived from the mutant (MT) and the respective wild-type (WT) construct. On the right, the corresponding cartoon of observed sequences is shown, with mutant at the top and wild type below (**exception for variant a**). Above the sequence, a cartoon of the minigene or midigene construct is presented; arrows depict the location of the primers used for RT-PCR. A black "x" represents the location of the variant. "E" stands for exon, flanking Rhodopsin (*RHO*) exons are depicted in white, *ABCA4* exons in gray, and insertions in red. "E30 M" denotes the full length exon 30, as described in NM_00350.2 (hg19), "E30 S" refers to a smaller exon 30, lacking the last 73 nucleotides p.(Cys1490Glufs\*12), which was observed in several transcripts.Fig. 2**Antisense oligonucleotide (AON)-mediated rescue for intronic** ***ABCA4*** **splice variants.** For three deep-intronic *ABCA4* variants (c.859--540C\>G, c.5197--557G\>T, and c.4539+1106C\>T), AON rescue experiments on transfected HEK 293-T cells were undertaken (**a**--**c**). AON experiments were also performed on the fibroblasts of a patient with c.\[4539+1106C\>T\];\[6089G\>A\] and control fibroblasts (**d**). A gel image is shown on the left, depicting the reverse transcription polymerase chain reaction (RT-PCR) product derived from mutant (MT) and wild-type (WT) midigene construct after transfection with three different AONs (*HEK*: untransfected HEK 293-T, *MQ: negative control* PCR, *NT*: nontransfected cells, *SON:* sense oligonucleotide). Rhodopsin (*RHO*) and actin (*ACTB*) were used as loading controls for RT-PCR products derived from experiments on HEK 293-T cells and fibroblasts, respectively. In fibroblasts, cycloheximide (CHX) was added. On the right, resulting RT-PCR products after AON rescue experiments are semiquantified using capillary analysis, using the ratio WT transcript/transcript including pseudo-exon (PE). If multiple PE containing transcripts were formed, they are grouped together in one PE group.Table 1Overview of functionally validated splice variantsc.notationg.notation (hg19/chr1)IntronEffect on splicingr.notationp.notationSize PE/ skipped exonc.position PE startc.position PE stopRecurrence and AF in our cohort (*n* = 67)Recurrence in Dutch cohort (*n* = 36)GoNL frequency (*n* = 499)1000 Genomes EUR frequency (*n* = 669)gnomAD NFE frequency (*n* = 7498)Functional assaysc.161--23T\>Gg.94577158A\>C2Exon 3 skipr.\[=, 161_302del\]p.\[=, Cys54Serfs\*14\]1421613021 (0.7%)0 (0%)/**//**This studyc.769--784C\>Tg.94549781G\>A6Inclusion PEr.\[=, 768_769ins769-617_769-778\]p.\[=, Leu257Aspfs\*3\]162769--778769--6171 (0.7%)7 (9.7%)0.8%0.7%0.4%Sangermano et al. this issuec.859--540C\>Gg.94546814G\>C7Inclusion PEr.858_859ins859-545_859-685;p.(Phe287Tyrfs\*33)141859--685859--5451 (0.7%)0 (0%)//This studyc.3191--11T\>Ag.94508465A\>T21Inclusion 9 bpr.3190_3191ins3191-1_3191-9,p.(Gly1064delins ValProProGly)93191--93191--11 (0.7%)0 (0%)///This studyc.4253+43G\>Ag.94496509C\>T28Exon 28 skipr.\[=, 4129_4253del\]p.\[=,Ile1377Hisfs\*3\]125412942538 (6%)9 (12.5%)0.5%0.1%0.5%Sangermano et al. this issuec.4539+1106C\>Tg.94493895G\>A30Inclusion PEr.\[4539_4540ins4539+1033_4539+1100; r.4539_4540ins4539+989_4539+1100\]p.\[Arg1514Glyfs\*3; p.Arg1514Valfs\*31\]68; 1124539+1033; 4539+9894539+1100; 4539+11002 (1.5%)0 (0%)///This study; Sangermano et al. this issuec.4539+2001G\>Ag.94493000C\>T30Inclusion PEr.\[=, 4539_4540ins4539+1891_4540-2162\]p.\[=, Arg1514Leufs\*36\]3454539+18914540--21627 (5.2%)1 (1.4%)//0.000666578%Albert et al. 2018c.4539+2064C\>Tg.94492937G\>A30Inclusion PEr.\[=, 4539_4540ins4539+1891_4540-2162\]p.\[=, Arg1514Leufs\*36\]3454539+18914540--21622 (1.5%)0 (0%)///This studyc.5197--557G\>Tg.94481967C\>A36Inclusion PEr.5196_5197ins5197-563_5197-750p.(Met1733\*)1885197--7505197--5631 (0.7%)0 (0%)/**//**This studyDifferent notations, effect on splicing, recurrence in the selected cohort of this study and of a Dutch cohort (Sangermano et al. this issue), both mainly composed of monoallelic patients are represented.^[@CR26],[@CR38]^ *AF* allele frequency, *GoNL* Genome of the Netherlands database, *gnomAD NFE* the Genome Aggregation Database (gnomAD) non-Finnish European population, *PE* pseudo-exon, *1000 Genomes EUR* 1000 Genomes European population.

### Three variants near coding exons of *ABCA4* {#Sec23}

Three splice variants are located within 50 bp of a canonical splice site of *ABCA4*. Both c.161--23T\>G (intron 2) and c.4253+43G\>A (intron 28) barely reduce the strength of the nearest canonical splice site but have a predicted effect on ESE binding and break silencer motifs. Splice assays reveal partial exon skipping for both variants (Fig. [1](#Fig1){ref-type="fig"} and Sangermano et al. this issue), predicted to induce a frameshift (Table [1](#Tab1){ref-type="table"}). \[[@CR38]\] The c.161--23T\>G variant occurs in a patient who carries the complex allele c.\[2588G\>C;5603A\>T\] (p.\[Gly863Ala, Gly863del; Asn1868Ile\]) in *trans* (Table [S1](#MOESM1){ref-type="media"}) (ref. ^[@CR8]^). In 5/8 patients c.4253+43G\>A is likely in *cis* with c.6006--609T\>A, a variant for which no splice effect could be observed (Sangermano et al. this issue).^[@CR20],[@CR38]^ Segregation of this complex allele in *trans* with the pathogenic allele c.5461--10T\>C in affected siblings (*p* = 2) as well as in an unaffected parent in the same family, and in a homozygous state in an unaffected sibling supports a hypomorphic nature of this complex allele (Figure [S6](#MOESM3){ref-type="media"}). The c.3191--11T\>A variant weakens the canonical acceptor splice site (ASS) of exon 22 and creates a strong novel ASS, leading to a 9-bp insertion in the mutant transcript as observed by minigene assays. This variant co-occurs with c.6089G\>A p.(Arg2030Gln) in a STGD1 patient.^[@CR8]^

### Four deep-intronic variants strengthen a cryptic splice site {#Sec24}

The deep-intronic variants c.859--540C\>G (intron 7), c.4539+1106C\>T (intron 30), and c.5197--557G\>T (intron 36) create or strengthen cryptic donor splice sites (DSSs) while c.769--784C\>T (intron 6) impacts an ASS.

The DSSs created or strengthened by c.859--540C\>G, c.4539+1106C\>T, and c.5197--557G\>T are located downstream to a strong cryptic ASS, generating pseudo-exons (PEs) of 141 bp, 68 bp, and 188 bp respectively, as confirmed via midigene assays (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). Furthermore, c.4539+1106C\>T creates another, less abundant PE (112 bp) due to the usage of another cryptic ASS (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). All included PEs harbor a premature termination codon (PTC), most likely resulting in the aberrant transcript undergoing NMD.

Specifically, c.859--540C\>G occurs in *trans* with c.4539+2001G\>A (V4) in a patient without prior identified *ABCA4* pathogenic variants. The c.4539+1106C\>T variant was identified in two unrelated STGD1 patients, in *trans* with either c.6089G\>A; p.(Arg2030Gln) or c.5882G\>A; p.(Gly1961Glu).

The c.5197--557G\>T variant is located in known minor exon 36.2, in which no variants have been yet identified, as opposed to minor exon 36.1 (Figure [S7](#MOESM3){ref-type="media"}) (ref. ^[@CR19]^). Here it was found in *trans* with c.5917del p.(Val1973\*).

Variant c.769--784C\>T (intron 6) strengthens an ASS, upstream to a strong cryptic DSS, inducing a PE (162 bp) in only a minority of messenger RNA (mRNA) from the mutant construct (Table [1](#Tab1){ref-type="table"}, Sangermano et al. this issue).^[@CR38]^ Because this variant likely occurs in *cis* with the hypomorphic c.5603A\>T p.(Asn1868Ile) in the genotype c.\[1454del\];\[769--784C\>T;5603A\>T\], the pathogenicity of this variant is currently considered unclear.

### Two deep-intronic variants affect splice enhancers and/or silencers {#Sec25}

Variant c.4539+2001G\>A (V4) (*n* = 7) is a known Belgian founder variant leading to a recently described PE inclusion (345 bp), similar to c.4539+2028C\>T (V5) (refs. ^[@CR21],[@CR26]^). Variant c.4539+2064C\>T (*n* = 2) is located within the same PE. Both have a predicted effect on ESE binding but while V4 is predicted to create ESEs and abolish splice silencers within this PE, c.4539+2064C\>T is predicted to create a novel silencer within this PE. Splice assays for the latter revealed several aberrant transcripts, two including the reported PE.^[@CR26]^

AON-mediated rescue in HEK 293-T cells and patient fibroblasts {#Sec26}
--------------------------------------------------------------

AON-mediated rescue was undertaken for c.859--540C\>G, c.4539+1106C\>T, and c.5197--557G\>T. Three different AONs were designed per variant, aimed at blocking ESE motifs and excluding the PE (Fig. [2](#Fig2){ref-type="fig"}, Table [S9](#MOESM1){ref-type="media"}). Rescue experiments were conducted in transfected HEK 293-T cells for all three variants, and in patient-derived fibroblasts for c.4539+1106C\>T.

The effect of c.859--540C\>G could be fully abolished by two AONs, and partially by AON3 (43.25%) (Fig. [2](#Fig2){ref-type="fig"}). For c.5197--557G\>T, all three AONs were able to restore normal splicing, with no detection of the mutant band in the AON1- and AON2-rescue (Fig. [2](#Fig2){ref-type="fig"}). AON-mediated rescue of c.4539+1106C\>T was undertaken in transfected HEK 293-T cells and patient-derived fibroblast cells (c.\[4539+1106C\>T\];\[6089G\>A\]). In HEK 293-T cells AON1 and AON2 restored the amount of normal transcript, while AON3 retained PE inclusions in the majority (86.7%) of the transcripts. In fibroblasts, AON2 showed the highest efficacy. AON-mediated correction of c.769--784C\>T and c.4253+43G\>A, can be found in Sangermano et al. (this issue), while AON rescue of the aberrant transcript caused by c.4539+2001G\>A (V4) was recently reported.^[@CR26],[@CR38]^

Filtering and functional analysis of putative *cis*-regulatory variants {#Sec27}
-----------------------------------------------------------------------

After functional analysis of 13 candidate splice variants, remaining variants were assessed for their presence within or near candidate regulatory regions within or flanking *ABCA4* (Table [S4; unpublished data:](#MOESM1){ref-type="media"}, Cherry et al., doi.10.1101/412361). After filtering, eight variants located within candidate regulatory regions remained, four of which were investigated using dual-luciferase reporter assays. Two additional variants outside of these regions were also selected because they were the only remaining rare candidate variants and are within predicted transcription factor binding sites (TFBSs). An overview of these six variants can be found in Table [S12](#MOESM1){ref-type="media"}.

After reporter assays, two variants showed significant downregulation of luciferase expression of mutant to WT transfected RPE-1 cells: c.2919--383C\>T (*n* = 1) and c.768+3223C\>T (*n* = 1), with an average reduction of the normalized (luciferase/*Renilla*) relative light unit (RLU) values of 36.9% (*p* = 0.004) and 32.3% (*p* \< 0.001) respectively (Figure [S3](#MOESM3){ref-type="media"}). Variant c.2919--383C\>T is located within a predicted ZNF143/STAF binding site, 18 bp adjacent to a predicted regulatory region (OREG0013611, chr1:94510701-94511661) with CTCF binding. It occurs in the following genotype c.\[5461--10T\>C;5603A\>T\];\[2919--383C\>T;5603A\>T\], sufficient to cause the late-onset phenotype observed and thus categorized as a potential modifying variant. Variant c.768+3223C\>T is located within a regulatory region that shows moderate WT activity within adult human retina (unpublished data, Cherry et al., doi.org/10.1101/412361). The variant is predicted to overlap with TFBSs such as RBL2 (PAZAR data set) and has predicted binding sites for FOXP2, POLR2A, and REST proteins (ChIP-Seq data, RegulomeDB). As the variant occurs in a patient without a coding *ABCA4* pathogenic variant, the implication of another disease gene cannot be ruled out (Figure [S6](#MOESM3){ref-type="media"}).

Identification and characterization of structural variants implicating *ABCA4* {#Sec28}
------------------------------------------------------------------------------

NGS-based CNV analysis was performed for all 67 patients. Furthermore, customized array-based high-resolution CNV analysis was used to investigate ten patients without a clear pathogenic noncoding sequence variant.^[@CR36]^ We identified six CNVs involving *ABCA4*, four of which are novel (Fig. [3](#Fig3){ref-type="fig"}, [S4,](#MOESM3){ref-type="media"} and [S8](#MOESM3){ref-type="media"}; Table [2](#Tab2){ref-type="table"}). A 5305-bp deletion of exon 5 was found in one monoallelic patient, c.442+799_c.570+541del. Exon 5 deletions have been previously reported in a Dutch STGD1 cohort.^[@CR3],[@CR10]^ A novel deletion spanning exons 10--11 was identified in one patient, c.1239+291_1555-5574del (10,140 bp). This predicted in-frame deletion occurs in *trans* with c.122G\>A; p.(Trp41\*). A 4024-bp deletion of exons 20--22 was identified (c.2918+775_3328+640del), revealing a known recurrent deletion.^[@CR3],[@CR7],[@CR10]^ Another novel deletion (exons 40--50) was identified and characterized at the nucleotide level, c.5585--166\_\*1254del (19,112 bp). It eliminates the 3′UTR of the mRNA, most likely rendering the resulting transcript unstable and occurs in *trans* with the complex allele c.\[2588G\>C;5603A\>T\] (p.\[Gly863Ala, Gly863del;Asn1868Ile\]).Fig. 3Schematic overview of the *ABCA4* deletions and duplications identified in this study. *ABCA4* exons involved in the deletions (**a-d**) and duplications (**e**, **f**) identified in this study are visualized in red and blue, respectively. The localization of the primers used to perform a junction polymerase chain reaction (PCR) and to delineate the copy-number variants (CNVs) are depicted as black arrows; nucleotides on the cartoons represent microhomology at the boundaries. The orientation of the tandem duplications toward *ABCA4* is the most likely one based on (non)amplification of several junction regions (data not shown). *InsA*: insertion of an A at a CNV junction.Table 2Overview of the CNVs identified in this study, including two novel deletions and two novel duplicationsc.notationg.notation (hg19/chr1)*ABCA4* introns--exons involvedSizeEffect on proteinp.notation (hg19)Number of patientsc.442+799_c.570+541delg.94568030-94573334delIntron 4--intron 55305 bpOut-of-framep.(Gly148Valfs\*89)1c.1239+291_1555-5574del^a^g.94534447-94544587delIntron 9--intron 1110,141 bpIn-framep.(Ala414_Glu518del)1c.2918+775_3328+640delg.94507677_94511700delIntron 19--intron 224024 bpOut-of-framep.(Ser974Glnfs\*64)1c.5585-166\_\*1254del^a^g.94457539-94476651delIntron 39--3′UTR19,113 bpOut-of-framep.(Gly1862Ter)1c.66+520_67-389dup^a^g.94579011-94586016dupIntron 17006 bpNAp.(?)1c.67-975_769-4582dup{insA}^a^g.94553579-94579597dup{insA}Intron 1--intron 626,019 bpIn-framep.(Ile23_Val256dup)1*bp* base pairs, *CNV* copy-number variant, *del* deletion, *dup* duplication, *NA* not applicable, *UTR* untranslated region.^a^Novel.

A duplication of over 26 kb (exons 2--6) was identified, starting within the first intron of *ABCA4*, c.67--975_769-4582dup{insA}. At the junction an information scar (insertion of an A) could be found. This in-frame tandem duplication is found in *trans* with the missense variant c.5381C\>A; p.(Ala1794Asp) in a patient. Another duplication located within intron 1 was identified in a STGD1 patient carrying the c.5714+5G\>A allele (Table [S1](#MOESM1){ref-type="media"}). Characterization of the junction showed a tandem noncoding duplicated region of 7006 bp, c.66+520_67-389dup.

A bioinformatics analysis reveals microhomology at the breakpoints of all deletions and the non-coding duplication, corresponding with a replicative-based CNV mechanism (Figure [S5](#MOESM3){ref-type="media"}). Duplication c.67-975_769-4582dup{insA} is likely due to nonhomologous end joining (NHEJ), as there is both microhomology and an information scar at the junction (Tables [S13](#MOESM1){ref-type="media"} and [S14](#MOESM1){ref-type="media"}).

The hypomorphic *ABCA4* allele c.5603A\>T as a second pathogenic variant {#Sec29}
------------------------------------------------------------------------

After removing patients solved with pathogenic splice or structural variants (27/67, 40.3%), 40 patients remained unsolved (Figure [S1](#MOESM3){ref-type="media"}). The hypomorphic c.5603A\>T p.(Asn1868Ile) variant was recently found to be the potential second missing allele in over 50% of monoallelic STGD1 cases.^[@CR23]^ When in *trans* to a complete loss-of-function *ABCA4* allele, this variant was shown to often lead to a late-onset phenotype. Here, it occurs as a possible *trans* allele in 29 of the remaining 40 patients (72.5%), even in a few cases that do not strictly meet all three criteria proposed: (1) late age of onset (\>35 years), (2) complete loss-of-function of the first allele, and (3) foveal sparing. The segregation of this hypomorphic variant in *trans* with a pathogenic variant is clear in 50% of the cases; for the remaining patients this is undetermined (Table [S1](#MOESM1){ref-type="media"}). While the average age of onset (AOO) of the patients solved with pathogenic deep-intronic splice variants and CNVs is 22.5 years, the average AOO of these 29 patients is 41 years, with 19/29 patients having an AOO \>35 years. These findings suggest that c.5603A\>T can be considered to be the missing allele in up to 43.3% (29/67) of the initial cohort.

DISCUSSION {#Sec30}
==========

In this study, we aimed to elucidate the missing heritability in a cohort of molecularly unsolved STGD1 patients using a locus-specific analysis targeting a syntenic region comprising *ABCA4* and its putative *cis*-regulatory domain.^[@CR28]^ This approach led to a molecular diagnosis in 83.6% (56/67) of patients. Noncoding splice variants and distinct CNVs account for the missing allele in 31.3% (21/67) and 9% (6/67) respectively, while the hypomorphic variant c.5603A\>T likely contributes to another 43.3% (29/67) of the missing alleles. Two *cis*-regulatory variants and one deep-intronic splice variant with potential modifying effect were identified in three patients.

In the category of noncoding splice variants, nine distinct variants were found, six of which were novel (c.161--23T\>G, c.769--784C\>T, c.859--540C\>G, c.3191--11T\>A, c.4539+1106C\>T, and c.5197--557G\>T) and three previously described as (possibly) disease-associated (c.4253+43G\>A, c.4539+2001G\>A, or V4, c.4539+2064C\>T).^[@CR19],[@CR20],[@CR39]^ For all nine variants a splice effect was demonstrated via splice assays either in this study, by Sangermano et al. this issue (c.769--784C\>T, c.4253+43G\>A) or by Albert et al.^[@CR26],[@CR38]^(c.4539+2001G\>A). Six variants lead to PE inclusion into the transcript, all introducing a PTC; two variants induce (partial) exon skipping, leading to a frameshift and the introduction of a PTC; and lastly, one variant creates an in-frame insertion of three amino acids. Given the minor amount of aberrantly spliced transcript observed for the c.769--784C\>T variant and its occurrence on the genotype c.\[1454del\](;)\[5603A\>T\], its pathogenicity is currently considered unclear.

One of the spinouts of the identification of noncoding splicing variants is their potential to function as therapeutic targets for AON-mediated rescue. AON treatment for inherited diseases, including Duchenne muscular dystrophy, spinal muscular atrophy, and more recently Usher syndrome and Leber congenital amaurosis, has been or is being introduced in the clinic. Here, we used AON rescue to successfully correct the aberrant splicing induced by the variants c.859--540C\>G, c.4539+1106C\>T, and c.5197--557G\>T in HEK 293-T cells and in patient-derived fibroblast cells carrying the c.4539+1106C\>T variant. These results are of interest to patients, offering the potential to restore the amount of correct mRNA and subsequently of ABCA4 protein required for normal function in vivo.

Besides noncoding splice variants, we investigated the contribution and effect of putative *cis*-regulatory variants. Two noncoding deep-intronic variants (c.768+3223C\>T and c.2919--383C\>T) showed a significant downregulation using in vitro reporter studies in RPE-1 cells. It is unclear however if these assays in RPE-1 cells recapitulate the biological effect on *ABCA4* expression in vivo. Even if the observed reduction is similar for both variants, the tested regulatory element in which c.768+3223C\>T is located has a stronger basal expression and might thus have a larger effect on the overall *ABCA4* expression.

Although *ABCA4* variants represent one of the most prevalent causes of inherited retinal disease, its variant spectrum is characterized by a scarcity of structural variants (SVs), with only nine deletions and one complex rearrangement reported.^[@CR3],[@CR7],[@CR10]--[@CR18],[@CR40]^ Using a NGS CNV pipeline and high-resolution array-based CNV analysis, we identified six distinct CNVs in our cohort of monoallelic patients: four deletions, two of which are novel and two novel duplications. Interestingly, one of them is a noncoding tandem duplication located within the first intron of *ABCA4* and encompassing several TFBSs. Delineation of the identified CNVs allowed an extensive bioinformatics analysis of their breakpoint regions revealing replicative-based mechanisms for all deletions and for the noncoding duplication, while the duplication spanning exons 2--6 most likely originated due to NHEJ. Next, we investigated the role of the hypomorphic c.5603A\>T variant in the remaining cohort and identified it as a putative second allele in \>72% of the remaining patients and \>43% of the initial cohort, confirming its enrichment and clinical significance in monoallelic STGD1 patients, as recently described.^[@CR23]^

Despite our approach, the molecular diagnosis remains uncertain in 11/67 (16.4%) patients. Some variants remain to be investigated via additional functional assays while other, more prevalent variants (MAF \>1%) or splice variants without clear predictions have not been scrutinized in this study. Finally, it cannot be excluded that a subset of patients have pathogenic variants in other genes, representing phenocopies with a phenotype resembling *ABCA4*-associated disease.

To conclude, this study demonstrates that a locus-specific integrated approach combining genomics with downstream tailored functional studies is powerful for elucidating a major portion of missing heritability in *ABCA4*-associated disease. The discovery of novel pathogenic variants in noncoding regions and the development of AONs can be envisaged for personalized therapies. Overall, this *ABCA4*-oriented study can be regarded as a model for missing heritability in other autosomal recessive diseases with a recognizable phenotype and with an incomplete molecular diagnosis.
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